Voloridge Investment Management, LLC Exelixis, Inc. Transaction History

Voloridge Investment Management, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$19.25 - $24.13 $2.73 Million - $3.42 Million	141,928 Added 51.05%	419,963 $10.1 Million
Q3 2023 Nov 14, 2023	BUY	$19.04 - $22.74 $4.66 Million - $5.56 Million	244,712 Added 734.36%	278,035 $6.08 Million
Q2 2023 Aug 14, 2023	SELL	$18.17 - $20.48 $1.17 Million - $1.32 Million	-64,664 Reduced 65.99%	33,323 $636,000
Q1 2023 May 15, 2023	BUY	$16.3 - $19.41 $1.6 Million - $1.9 Million	97,987 New	97,987 $1.9 Million
Q1 2022 May 16, 2022	SELL	$17.03 - $22.67 $179,666 - $239,168	-10,550 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$15.84 - $21.88 $3.45 Million - $4.76 Million	-217,581 Reduced 95.38%	10,550 $193,000
Q3 2021 Nov 15, 2021	BUY	$16.3 - $21.14 $3.72 Million - $4.82 Million	228,131 New	228,131 $4.82 Million
Q4 2020 Feb 16, 2021	SELL	$18.39 - $24.8 $6.08 Million - $8.2 Million	-330,665 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$20.67 - $26.94 $3.04 Million - $3.96 Million	147,007 Added 80.04%	330,665 $8.09 Million
Q2 2020 Aug 14, 2020	BUY	$16.46 - $27.42 $3.02 Million - $5.04 Million	183,658 New	183,658 $4.36 Million

503

244M

2.54M

2.29M

Ticker EXEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 321,832,000
Market Cap $11.6B
Description
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...

Get notified when there are updates to the investment portfolio of Voloridge Investment Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Voloridge Investment Management, LLC with notifications on news.